A Treatment With No Proof — Until Now
The main drug doctors have used for decades is called pyridostigmine (pie-rid-oh-STIG-meen). Most people with MG take it daily. It helps signal muscles to contract more effectively. And yet, until this study, there was no rigorous randomized controlled trial — the gold standard of medical evidence — proving it actually worked.
That is not a typo. A drug prescribed to hundreds of thousands of people around the world had never been proven in the kind of trial we require for new drugs today.
What Changed and Why It Matters
For years, doctors believed pyridostigmine worked based on decades of clinical experience and patient-reported improvement. That belief turned out to be correct. But here's the twist: no one had ever formally tested it against a placebo in a controlled setting.
The concern was practical and ethical. How do you withhold a medication from patients who depend on it? Researchers at Leiden University Medical Center in the Netherlands designed a clever workaround: a crossover trial, where every participant received both pyridostigmine and placebo — just in different short periods, separated by a washout phase. That way, no one went without their usual treatment for long.
Think of the connection between a nerve and a muscle as a doorbell system. The nerve rings the doorbell by releasing a chemical called acetylcholine. The muscle answers by contracting. In MG, the immune system blocks the doorbell receptor on the muscle side. The nerve keeps ringing, but the muscle doesn't always hear it.
Pyridostigmine works by slowing down the enzyme that clears acetylcholine from the gap between nerve and muscle. More acetylcholine stacks up, giving it more chances to reach any remaining receptors. The doorbell rings more insistently — and the muscle is more likely to respond.
The Study Snapshot
Nineteen adults with antibody-positive MG — meaning they had the most common, well-understood form of the disease — took part in the trial. Each person used their usual dose of pyridostigmine. They were randomly assigned to receive either their medication or an identical placebo for five days, then switched to the other condition for another five days, with a two-day washout in between. Researchers measured MG severity using four established clinical scales.
The results were clear across every measure. On the primary scale — the Myasthenia Gravis Impairment Index — pyridostigmine scored an average of 5.3 points better than placebo. On daily living tasks, on physical examination scores, and on quality-of-life ratings, participants consistently did better while on their medication than while on placebo.
These improvements were statistically robust. The confidence intervals — the range of likely true effects — did not overlap with zero on any measure. That means it is very unlikely the results were due to chance.
This doesn't mean the treatment is new — it means the evidence behind it is now far stronger.
A post-study analysis also found that using pyridostigmine saves money. Researchers estimated the drug reduces societal costs by around €6,500 per year per patient while also improving quality of life — adding an estimated 0.1 quality-adjusted life years annually.
Why This Evidence Matters
Some may wonder: if the drug works, why does the proof matter? The answer is that medicine operates on evidence. Insurers, guidelines, and clinical decisions all depend on data — not tradition. Without trial data, drugs can be deprioritized, underprescribed, or contested in cost-effectiveness discussions. This trial closes that gap. It gives patients, doctors, and healthcare systems a solid scientific foundation for a treatment that is already part of daily life for hundreds of thousands of people.
If you or someone you know has MG and takes pyridostigmine, this research is good news. It validates what many patients already experience. It also provides the kind of evidence that can support better access to the drug in health systems that require formal trial data before coverage decisions.
The study was small — only 19 participants — and conducted at a single specialized center in the Netherlands. Larger trials at multiple sites would help confirm these findings across a broader range of patients, including those with different disease severities or treatment histories.
This trial sets the stage for more rigorous study of the full MG treatment landscape. Researchers now want to understand which patients respond best to pyridostigmine, whether higher or lower doses make a difference, and how this drug interacts with newer immunotherapy treatments for MG. Clinical guidelines may be updated to reflect this Class I evidence — the highest quality of evidence in clinical research — and future trials may use this study's design as a model for testing other long-used but under-studied medications.
